|
US2021060023A1
|
|
Cycloalkyl-Diamines for the Treatment of Inflammation
|
|
US2021052594A1
|
|
Cycloalkyl-Diamines for the Treatment of Pain
|
|
US2016235759A1
|
|
Kappa opioid receptor compounds
|
|
US2016158209A1
|
|
Compounds for treatment of alzheimer's disease
|
|
US2016151308A1
|
|
Cycloalkyl-diamines for neurodegenerative disorders
|
|
US9283196B1
|
|
Cycloalkyl-diamines for CNS disorders
|
|
US2016237052A1
|
|
Histamine-3 Receptor Antagonists
|
|
US9169237B1
|
|
Antiprotozoal amidine compounds
|
|
US2016031844A1
|
|
Kappa opioid receptor compounds
|
|
US2015210626A1
|
|
Cycloalkyl-diamines
|
|
US2015038507A1
|
|
Antiprotozoal compounds
|
